Success Metrics

Active Trials

0(0%)

Phase Distribution

Ph phase_2

75%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

3(75.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 23 (75.0%)

Phase 31 (25.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials

Showing 4 of 4

unknownphase_2

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

NCT02636231

unknownphase_2

Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

NCT02745561

unknownphase_3

E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

NCT02630264

unknownphase_2

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

NCT01192230

Clinical Trials (4)

Showing 4 of 4 trials

NCT02636231Phase 2

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Unknown

NCT02745561Phase 2

Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

Unknown

NCT02630264Phase 3

E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Unknown

NCT01192230Phase 2

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Unknown

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4